USP Workshops Address Variety of Pharma Issues

News
Article

The US Pharmacopeial Convention is hosting a variety of workshops in Autumn 2017 on a wide range of topics including continuing education, bioassays, and peptides.

The US Pharmacopeial Convention (USP) will be hosting five workshops in the fall of 2017 that will address current scientific findings, regulatory trends, and public health issues. The workshops are open to anyone interested, and more information can be found on USP’s website.

The following workshops are available:

  • Re-thinking Pharmaceutical Technology Continuing Education, Sept. 14–15, 2017. This workshop, cosponsored by the National Institute for Pharmaceutical Technology and Education (NIPTE), will include presentations on NIPTE training programs and USP’s standardization and educational programs. Topics discussed will include pharmaceutical continuing education and education best practices.

  • USP’s 7th Bioassay Workshop–Bioassay: A Lifecycle Approach, Sept. 25–26, 2017. This workshop will take a look at how lifecycle and QbD perspectives are being incorporated into bioassays. Lifecycle methods from scientific, statistical, and regulatory perspectives will be discussed. 

  • Computer Modeling–In-vitro and In-vivo Studies, Oct. 23–25, 2017. This workshop will address how computer modeling and simulation can be useful tools to accelerate product development.

  • IPA Probiotic Workshop in DC, Oct. 26, 2017. Cosponsored by the International Probiotics Association, this workshop will foster open dialogue on how probiotics may be considered within regulations.

  • 4th USP Workshop on Synthetic Therapeutic Peptides: Regulations, Standards and Quality, Nov. 6­–7, 2017. Attendees will learn about USP’s standards and regulatory expectations for peptide products. Strategies for control of raw materials and impurities will be discussed.

Visit www.usp.org for more information.

Source: USP

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.